Archer Materials (ASX:AXE) partnered with UK-based electronics company Paragraf to develop the company's Biochip potassium ion sensor for testing chronic kidney disease, according to a Monday filing with the Australian bourse.
The agreement will be carried out in two stages, with each stage expected to take over three months at an estimated cost of AU$450,000, the filing said.
Shares were up 8% in midday trade Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.